{
    "clinical_study": {
        "@rank": "159880", 
        "acronym": "TACTT3", 
        "arm_group": [
            {
                "arm_group_label": "AM-101 injection", 
                "arm_group_type": "Experimental", 
                "description": "AM-101"
            }, 
            {
                "arm_group_label": "Placebo injection", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this research study is to test the safety and effectiveness of the study\n      drug, AM-101. AM-101 is tested for the treatment of tinnitus that started as the result of\n      an injury to the inner ear or due to middle ear inflammation (otitis media). Subjects with\n      tinnitus can take part in the study, if their tinnitus started within the last 3 months or\n      within the last 4 to 12 months."
        }, 
        "brief_title": "AM-101 in the Treatment of Acute Tinnitus 3", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Tinnitus", 
        "condition_browse": {
            "mesh_term": "Tinnitus"
        }, 
        "detailed_description": {
            "textblock": "This phase III study is assessing the drug's safety and is aiming to demonstrate efficacy of\n      repeated intratymanic AM-101 injections in the treatment of acute peripheral tinnitus (up to\n      3 months (Stratum A), or between 4 and 12 months (Stratum B) from onset)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Persistent subjective peripheral tinnitus  (unilateral or bilateral) following\n             traumatic cochlear injury (acute acoustic trauma, blast trauma, middle ear surgery,\n             inner ear barotrauma, tympanic membrane trauma) or otitis media with onset no longer\n             than 3 months (Stratum A) or between 3 months and 12 months (Stratum B) prior to\n             randomization\n\n          2. Age \u2265 18 years and \u2264 75 years;\n\n          3. Negative pregnancy test (woman of childbearing potential);\n\n          4. Willing and able to use adequate hearing protection, respectively to refrain from\n             engaging in activities or work involving loud noise exposure where sufficient hearing\n             protection is not possible or ensured;\n\n          5. Willing and able to protect ear canal and middle ear from water exposure as long as\n             tympanic membrane is not fully closed.\n\n        Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          1. Fluctuating tinnitus;\n\n          2. Intermittent tinnitus;\n\n          3. Tinnitus resulting from traumatic head or neck injury;\n\n          4. Presence of chronic tinnitus;\n\n          5. Meniere's Disease, history of endolymphatic hydrops, or history of fluctuating\n             hearing loss;\n\n          6. History of repeated idiopathic sudden sensorineural hearing loss or history of\n             acoustic neuroma;\n\n          7. Ongoing acute or chronic otitis media or otitis externa;\n\n          8. Other treatment of tinnitus for the study duration;\n\n          9. Known hypersensitivity, allergy or intolerance to the study medication or any history\n             of severe, abnormal drug reaction;\n\n         10. Women who are breast-feeding, pregnant or who are planning to become pregnant during\n             the study;\n\n         11. Women of childbearing potential who are unwilling or unable to practice\n             contraception, such as hormonal contraceptives, double barrier, sexual abstinence or\n             intercourse with a partner who has been vasectomised for at least three months;\n\n         12. Concurrent participation in another clinical study or participation in another\n             clinical study within 30 days prior to randomization.\n\n        Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040194", 
            "org_study_id": "AM-101-CL-12-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "AM-101 injection", 
                "description": "AM-101 gel for intratympanic injection", 
                "intervention_name": "AM-101", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo injection", 
                "description": "Placebo gel for intratympanic injection", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Munich", 
                    "country": "Germany"
                }, 
                "name": "Investigatigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 3", 
        "overall_contact": {
            "email": "auris-trials@medpace.com", 
            "last_name": "Medpace", 
            "phone": "+49 (0)89 89 55 718 0"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Austrian Medicines and Medical Devices Agency", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hungary: National Institute of Pharmacy", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Switzerland: Swissmedic"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Improvement in tinnitus loudness", 
                "measure": "Tinnitus loudness", 
                "safety_issue": "No", 
                "time_frame": "Day 84"
            }, 
            {
                "description": "Occurrence of deterioration in hearing threshold in the treated ear(s)", 
                "measure": "Hearing threshold", 
                "safety_issue": "Yes", 
                "time_frame": "Day 35"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040194"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of Responders", 
                "measure": "Responders", 
                "safety_issue": "No", 
                "time_frame": "Day 84"
            }, 
            {
                "description": "Improvement in tinnitus questionnaires", 
                "measure": "Tinnitus questionnaires", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 84"
            }, 
            {
                "description": "Improvement in tinnitus loudness", 
                "measure": "Tinnitus loudness", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 35"
            }, 
            {
                "description": "Difference in occurrence of deterioration in hearing threshold in the treated ear(s)", 
                "measure": "Hearing threshold", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 84"
            }, 
            {
                "description": "Occurence and severity of adverse events and serious adverse events", 
                "measure": "Adverse events and serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 84"
            }
        ], 
        "source": "Auris Medical, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Auris Medical AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}